James T. Kost, Ph.D.
Affiliations: | 2001 | University of Rochester, Rochester, NY |
Area:
StatisticsGoogle:
"James Kost"Parents
Sign in to add mentor| Michael P. McDermott | grad student | 2001 | Rochester | |
| (Order restricted inference using dependent contrasts.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Myers GJ, Davidson PW, Shamlaye C, et al. (2020) The Seychelles Child Development Study of methyl mercury from fish consumption: analysis of subscales from the Child Behaviour Checklist at age 107 months in the main cohort. Neurotoxicology. 81: 331-338 |
| Egan MF, Mukai Y, Voss T, et al. (2019) Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. Alzheimer's Research & Therapy. 11: 68 |
| Egan MF, Kost J, Voss T, et al. (2019) Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. The New England Journal of Medicine. 380: 1408-1420 |
| Stone JA, Kleijn HJ, Xu M, et al. (2019) Verubecestat Disease Progression Modeling From Apecs, A Phase 3 Trial In Prodromal Alzheimer’S Disease: No Dose- And Exposure-Dependency In Clinical Endpoints Alzheimers & Dementia. 15 |
| Egan MF, Kost J, Tariot PN, et al. (2018) Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. The New England Journal of Medicine. 378: 1691-1703 |
| Egan MF, Voss T, Kost J, et al. (2018) P4-013: Design Of A Phase-3 Trial (Apecs) To Evaluate The Bace Inhibitor Verubecestat In Prodromal Ad Alzheimers & Dementia. 14 |
| Egan M, Voss T, Mo Y, et al. (2016) Bace Inhibitor Verubecestat (Mk-8931): Baseline Characteristics For Participants Enrolled In The Phase Ii/Iii Epoch Alzheimer’S Disease Trial Alzheimers & Dementia. 12: 1183 |
| Marsico M, Kost J, Mozley LH, et al. (2016) Assessing Geographic Variability In Cognitive And Functional Baseline Scores In A Large Multinational Trial Of Mild-To-Moderate Alzheimer’S Disease Alzheimers & Dementia. 12: 761 |
| Sur C, Mo Y, Kost J, et al. (2016) Relationship Between Volumetric Mri Parameters, Apoe4 And Mmse Status At Baseline In The Verubecestat (Mk-8931) Mild To Moderate Alzheimer’S Disease Phase 2/3 Trial Alzheimers & Dementia. 12 |
| Anderson MS, Hanley WD, Moreau AR, et al. (2011) Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. British Journal of Clinical Pharmacology. 71: 616-20 |